[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-353293-105":3,"detail-sidebar-cat-0-en-105":80,"doc-detail-353293-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":73,"head_meta":75,"extra_data":77,"updated_unix":79},105,"en","exploring-pim1-kinase-as-a-therapeutic-target-mechanisms-and-strategies-in-cancer-treatment","Exploring PIM1 Kinase as a Therapeutic Target - Mechanisms and Strategies in Cancer Treatment","","Cancer remains a major global health challenge and the second leading cause of death worldwide. Targeted therapy offers precision, yet many current options face limited actionable targets and frequent drug resistance, while immunotherapy can show variable response rates and immune-related adverse events. This review focuses on PIM1 kinase, a key driver in tumor progression and poor prognosis. It systematically analyzes PIM1 mechanisms across apoptosis, cell-cycle control, DNA damage response, metastasis, stemness, metabolism, angiogenesis, immune regulation, and resistance. It further evaluates PIM1-targeting advances and proposes combination strategies using PIM1 inhibitors alongside agents acting on parallel or upstream/downstream pathways.",{"@graph":14,"@context":72},[15,34,55],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/exploring-pim1-kinase-as-a-therapeutic-target-mechanisms-and-strategies-in-cancer-treatment/353293/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/exploring-pim1-kinase-as-a-therapeutic-target-mechanisms-and-strategies-in-cancer-treatment/353293.png","ImageObject",300,407,{"name":42,"@type":43},"awa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":33},"InteractionCounter",{"@type":54},"ViewAction",{"@type":56,"mainEntity":57},"FAQPage",[58,64,68],{"name":59,"@type":60,"acceptedAnswer":61},"Why is PIM1 considered a promising therapeutic target in cancer?","Question",{"text":62,"@type":63},"PIM1 is a serine/threonine protein kinase overexpressed in many tumors and plays pivotal roles in oncogenic signaling, supporting tumor progression and poor prognosis.","Answer",{"name":65,"@type":60,"acceptedAnswer":66},"Which biological processes does the review say PIM1 regulates in tumors?",{"text":67,"@type":63},"The review summarizes PIM1 involvement in programmed cell death, cell-cycle progression, DNA damage response, metastasis, stemness, metabolic reprogramming, tumor angiogenesis, immune response, and therapeutic resistance.",{"name":69,"@type":60,"acceptedAnswer":70},"What future research strategy does the review propose for PIM1-targeted therapy?",{"text":71,"@type":63},"It proposes combination strategies using PIM1 inhibitors together with agents targeting parallel or upstream/downstream pathways regulated by PIM1.","https://schema.org",{"og:url":32,"og:type":74,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":76,"canonical":32},"index,follow",{"doc_id":78,"site_id":7},353293,1792185308,{"code":4,"msg":81,"data":82},"success",[83,87,91,95,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":84,"show_sort_weight":85,"slug":86},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":88,"show_sort_weight":89,"slug":90},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":92,"show_sort_weight":93,"slug":94},"Exam",70,"exam",{"id":96,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},5,"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":96,"slug":129},19,"General","general",{"code":4,"msg":81,"data":131},{"doc_id":78,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":33,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Review  \nExploring PIM1 Kinase as a Therapeutic Target: Mechanisms and Strategies in Cancer Treatment  \nTingyu Zeng †, Huayong Liu†, Zhipan Li, Tiange Liu, Kaifeng Zhang and Shuping Wang *  \nAcademic Editors: Mauro Salvi, Wei-Chien Huang and Josefa León  \nReceived: 3 May 2026  \nRevised: 4 July 2026  \nAccepted: 7 July 2026  \nPublished: 15 July 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nKey Laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China;  \n[tingyu_zeng@126.com](tingyu_zeng@126.com) (T.Z.); [17806087313@163.com](17806087313@163.com) (H.L.); [lzhipan2023@lzu.edu.cn](lzhipan2023@lzu.edu.cn) (Z.L.);  \n[liutg2023@lzu.edu.cn](liutg2023@lzu.edu.cn) (T.L.); [zhangkf2023@lzu.edu.cn](zhangkf2023@lzu.edu.cn) (K.Z.)  \n* [Correspondence: wangsp16@126.com](Correspondence: wangsp16@126.com)  \n† These authors contributed equally to this work.  \nAbstract  \nCancer remains a major global health challenge and is the second leading cause of death worldwide. Targeted therapy has emerged as one of the most promising strategies for cancer treatment. However, current targeted therapies highlight the urgent need for novel therapeutic targets and strategies. The provirus integration site for Moloney murine leukemia virus 1 (PIM1) kinase has been identified as a key factor in tumor progression and poor prognosis. This review systematically summarizes and analyzes the diverse mechanisms of PIM1 in promoting tumor progression, including cell programmed death, cell cycle progression, DNA damage response, metastasis, cell stemness, metabolic reprogramming, tumor angiogenesis, anti-cancer immune response and therapeutic resistance, and comprehensively evaluates its potential as a therapeutic target. Moreover, PIM1 contributes to the development of resistance to various anticancer therapies. Based on the advances and limitations in PIM1-targeted cancer therapy, we propose that future research should focus on combination strategies involving PIM1 inhibitors and agents targeting parallel or upstream/downstream pathways regulated by PIM1 . Our review highlights the therapeutic value and potential of PIM1 in cancer treatment, providing new insights and theoretical bases for the development of novel anti-tumor strategies targeting PIM1 .  \nKeywords: stemness; therapeutic resistance; PIM1; targeted therapy; immune response  \n1. Introduction  \nCancer remains the second leading cause of death worldwide, with tumors capable of originating from nearly any organ or tissue in the body. This occurs when abnormal cells grow uncontrollably, surpassing their normal boundaries, invading adjacent tissues, and/or spreading to distant organs, a process known as metastasis, which is the primary cause of cancer-related mortality [1] . Traditional cancer treatment modalities include surgery, chemotherapy, and radiotherapy [2] . While surgery and radiotherapy are effective local treatments for primary tumors, they are limited in their ability to address metastatic or micrometastatic lesions [3] . Moreover, radiotherapy can lead to severe complications such as radiation-induced pneumonitis, which may be life-threatening [4] . Chemotherapy, asa systemic approach, can target subclinical lesions and prevent recurrence and metastasis, but its non-selective cytotoxicity also damages normal cells and tissues [5] . With  \nthe advent of high-throughput omics technologies, targeted therapies and immunotherapies have brought new hope to cancer treatment. Targeted therapies offer precision by specifically acting on molecular targets unique to cancer cells, thereby reducing collateral damage to normal tissues and minimizing the side effects associated with conventional chemotherapy [6] . Imm","cbCaifeKcjdqcWEK","https://ap.wps.com/l/cbCaifeKcjdqcWEK","pdf",1303286,26,"English","# Abstract\n# Keywords\n# 1. Introduction","[{\"question\":\"Why is PIM1 considered a promising therapeutic target in cancer?\",\"answer\":\"PIM1 is a serine/threonine protein kinase overexpressed in many tumors and plays pivotal roles in oncogenic signaling, supporting tumor progression and poor prognosis.\"},{\"question\":\"Which biological processes does the review say PIM1 regulates in tumors?\",\"answer\":\"The review summarizes PIM1 involvement in programmed cell death, cell-cycle progression, DNA damage response, metastasis, stemness, metabolic reprogramming, tumor angiogenesis, immune response, and therapeutic resistance.\"},{\"question\":\"What future research strategy does the review propose for PIM1-targeted therapy?\",\"answer\":\"It proposes combination strategies using PIM1 inhibitors together with agents targeting parallel or upstream/downstream pathways regulated by PIM1.\"}]","Exploring PIM1 Kinase as a Therapeutic Target - Mechanisms and Strategies in Cancer Treatment | PDF",1790104500,66,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c698c21da9650974a9200ca3d565127.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fce2832e6c1cbd8ac4120a82c48e178c.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/735369566ebb6ceca793ac69acf3a808.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6e16b16230830f620b06f84b840433f.webp",980,1385]